Translational Animal Models of Atopic Dermatitis (AD) for Preclinical Studies
Speaker: Luke Yu, MD, Ph.D.
Global head of Preclinical Pharmacology, Biocytogen Boston Corp & Biocytogen Pharmaceuticals
Atopic Dermatitis is a chronic inflammatory skin condition characterized by redness, cracking, and scaling, often leading to painful sores. While the precise cause of AD remains unclear, a dysfunctional epidermal barrier and dysregulated immune responses (including IL-4, IL-13, IL-25, IL-33, and IFN-g) are thought to influence the onset and severity of the disease. Various therapeutic options, encompassing both topical and systemic immunosuppressants, are employed to manage AD symptoms. However, the need for more targeted and personalized treatments remains.
To advance our understanding of the determinants of AD and explore new treatments, numerous translational animal models have been established to recapitulate disease symptoms and profile changes in immune cell subtypes in response to novel therapeutic candidates. In this webinar, we reviewed the underlying mechanisms of these models, explored their advantages, and offered insights into their potential use based on specific research objectives.
